Alto Neuroscience reports positive outcomes from Phase IIb trial of MDD therapy

Alto Neuroscience has reported positive outcomes from the interim analysis of its double-blind Phase IIb trial of oral ALTO-300, as an adjunctive treatment for major depressive disorder (MDD).